Industry Developments

BMI View: We believe that strengthened legislation controlling the advertisement of prescription and over-the-counter (OTC) medicines will benefit Uzbekistan's pharmaceutical market... 2011-06-16

BMI View: Latvia's disease profile and relatively low per-capita consumption of pharmaceuticals (compared with the rest of developed Europe) is a clear illustration of the need for... 2011-06-07

BMI View: The outlook for Belarus's pharmaceutical market has changed from moderately positive to dire. The rapid fall of the Belarusian ruble against the US dollar has left Belarus... 2011-06-01

BMI View: We now believe that Hungarian generic drugmaker Gedeon Richter's stock is undervalued. The company's share price has underperformed as investors have been wary of domestic... 2011-05-27

BMI View: It is certainly a brave company that purchases a Greek drugmaker in the middle of an economic crisis which has had such a major impact on the local pharmaceutical market.... 2011-05-26

BMI View: We view Valeant's move to purchase Lithuanian company Sanitas favourably, particularly in the wake of its failed hostile bid for Cephalon earlier in 2011.The premium Valeant... 2011-05-25

BMI View: We believe that the Hungarian government's aim to decrease pharmaceutical subsidies by increasing the burden on drugmakers, and attempting to avoid any form of increased patient... 2011-05-24

BMI View: Our view that Greece's pharmaceutical market is set for a decade of decline remains firmly in play. The list of challenges is sizeable: the combination of price erosion mechanisms;... 2011-05-23

BMI View: Investors hoping to capitalise on emerging market growth stories should be wary of Turkish pharmaceutical firms. Significant cuts to drug prices and reimbursement controls,... 2011-05-20

BMI View: In most emerging marketing, doctors are being increasingly targeted by pharmaceutical sales representatives. However, legislation set to be introduced in Russia would halt... 2011-05-19